/
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI (maralixibat) ( Livmarli ), CHOLBAM (cholic acid) capsules ( Cholbam ), and CTEXLI (chenodiol) tablets ( Ctexli ).
The business is unprofitable at the operating level (-4.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 54.7% YoY with margins expanding 21.8pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$570M
▲ +54.7% YoY
Net Income (TTM)
-$799M
▲ +73.4% YoY
Op. Margin
-139.82%
▲ +21.8pp YoY
ROIC
-105.51%
▲ +9.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$173M
▲ +488.0% YoY
Op. Cash Flow (TTM)
-$171M
▲ +440.7% YoY
Net Debt
-$62M
Net Cash Position
Cash & Equiv.
$386M
Continue Research